Age-related macular degeneration: Epidemiology and optimal treatment

Drugs and Aging

Volumn 19, Issue 2, 2002, Pages 101-133

  La Cour, Morten ^a   Kiilgaard, Jens Folke ^b   Nissen, Mogens Holst ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CARDIOVASCULAR DISEASE; CAUCASIAN; DISEASE COURSE; FLUORESCENCE ANGIOGRAPHY; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HUMAN; INCIDENCE; LASER COAGULATION; LASER SURGERY; NUTRITIONAL STATUS; PATHOGENESIS; PHENOTYPE; PHOTODYNAMIC THERAPY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SMOKING; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 0036253277     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219020-00003     Document Type: Review

References (350)

1. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-TAP report 2
2. Verteporfin therapy of subfoveal choroidal neovascularization in age- related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2
3. Epidemiology of AMD
4. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975
5. Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors
6. An international classification and grading system for age-related maculopathy and age-related macular degeneration
7. The Wisconsin age-related maculopathy grading system
8. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye study
9. Bilateral involvement by age related maculopathy lesions in a population
10. Prevalence of age-related maculopathy. The Beaver Dam Eye study
11. The prevalence of age-related maculopathy in the Rotterdam Study
12. Fluorescein angiography
13. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration
14. Evolution of soft drusen in age-related macular degeneration
15. Refractive error and age-related maculopathy: The Blue Mountains Eye study
16. Histopathologic features
17. Evolution of geographic atrophy of the retinal pigment epithelium
18. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study
19. Age-related macular degeneration and choroidal neovascularization
20. The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration
21. Laser treatments with verteporfin therapy and its potential impact on retinal practices
22. Clinicopathological correlation in exudative age related macular degeneration: Histological differentiation between classic and occult choroidal neovascularisation
23. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes
24. Aldersrelateret makula-degeneration en folkesygdom
25. Indocyanine green angiography
26. Analysis of vascularized pigment epithelial detachments using indocyanine green videoangiography
27. Clinicopathologic correlation of choroidal neovascularization demonstrated by indocyanine green angiography in a patient with retention of good vision for almost four years
28. Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments
29. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration
30. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy
31. Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments
32. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration
33. Pattern of age-related maculopathy in the macular area. The Beaver Dam Eye study
34. Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study
35. Age-related maculopathy in a multiracial United States population: The National Health and Nutrition Examination Survey III
36. The prevalence of age-related maculopathy by geographic region and ethnicity. The Colorado-Wisconsin Study of Age-Related Maculopathy
37. The second eye of Japanese patients with unilateral exudative age related macular degeneration
38. Report on the nationwide epidemiological survey of exudative age-related macular degeneration in Japan
39. Features of age-related macular degeneration in a black population
40. Racial differences in the prevalence of age-related macular degeneration: The Baltimore Eye Survey
41. Prevalence and causes of blindness in Greenland
42. Prevalence of blindness caused by senile macular degeneration in Greenland
43. Age-related macular degeneration in Inuit
44. The grading and prevalence of macular degeneration in Chesapeake Bay watermen
45. The prevalence of age-related maculopathy: The visual impairment project
46. Smoking and age-related macular degeneration. The POLA study
47. Risk factors for age-related macular degeneration: Pooled findings from three continents
48. Prevalence and visual consequences of macular changes in a population aged 70 years and older
49. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study
50. The five-year incidence and progression of age-related maculopathy: The Beaver Dam Eye study
51. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye study
52. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity
53. The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey
54. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation study
55. Visual impairment of age-related macular degeneration. An epidemiological study of 1000 aged individuals
56. Age-related macular degeneration and blindness due to neovascular maculopathy
57. Senile macular degeneration: A case-control study
58. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity
59. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors
60. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization
61. Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollern
62. The incidence of registered blindness caused by age-related macular degeneration
63. Seven year follow-up of age-related maculopathy in an elderly British population
64. Early drusen formation in the normal and aging eye and their relation to age related maculopathy: A clinicopathological study
65. Prognosis of patients with bilateral macular drusen
66. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial
67. Choroidal neovascularization in the Choroidal Neovascularization Prevention Trial
68. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration
69. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials
70. New visual acuity charts for clinical research
71. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials
72. Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP report
73. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration
74. Occult subretinal new vessels in age-related macular degeneration. Natural history and early laser treatment
75. Natural history
76. Pathogenesis of disciform detachment of the neuroepithelium. I general concepts and classifications
77. Ageing and degeneration in the macular region: A clinico-pathological study
78. Natural history of macular subretinal hemorrhage in age-related macular degeneration
79. Variations in the clinical course of submacular hemorrhage
80. Geographic atrophy
81. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration
82. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration
83. Epidemiology
84. Gender, oestrogen, hormone replacement and age-related macular degeneration: Results from the Blue Mountains Eye study
85. The genetics of age-related macular degeneration
86. Family history and age-related maculopathy: The Blue Mountains Eye study
87. Genetic risk of age-related maculopathy. Population-based familial aggregation study
88. Familial aggregation of age-related maculopathy
89. Is genetic predisposition an important risk factor in age-related macular degeneration?
90. Age related macular degeneration in monozygotic twins and their spouses in Iceland
91. Heredity and age-related macular degeneration. Observations in monozygotic twins
92. A twin study of age-related macular degeneration
93. Genetic association of apolipoprotein E with age-related macular degeneration
94. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration
95. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration
96. Further evidence for an association of ABCR alleles with age-related macular degeneration. The International ABCR Screening Consortium
97. Allelic variation in ABCR associated with Stargardt disease but not age-related macular degeneration
98. ABCR gene analysis in familial exudative age-related macular degeneration
99. Allelic variation in the VMD2 gene in best disease and age-related macular degeneration
100. A full genome scan for age-related maculopathy
101. Associations of antioxidant enzymes with cataract and age-related macular degeneration. The POLA Study
102. Risk factor analysis for atrophic and exudative age-related macular degeneration. An epidemiological study of 1000 aged individuals
103. Risk factors for neovascular age-related macular degeneration
104. Risk factors associated with age-related macular degeneration: A case-control study in the age-related eye disease study: Age-related eye disease study report number 3
105. Smoking is also associated with age-related macular degeneration in persons aged 85 years and older: The Rotterdam Study
106. The Beaver Dam Eye Study: The relation of age-related maculopathy to smoking
107. Smoking and age-related maculopathy. The Blue Mountains Eye Study
108. Age-related macular degeneration and smoking. The Rotterdam Study
109. A prospective study of cigarette smoking and age-related macular degeneration in women
110. A prospective study of cigarette smoking and risk of age-related macular degeneration in men
111. Case-control study of the risk factors for age related macular degeneration
112. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study
113. Cataracts and macular degeneration in older Americans
114. Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey
115. Systemic hypertension and age-related maculopathy in the Framingham Study
116. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: The Blue Mountains Eye Study
117. Risk factors of age-related maculopathy in a population 70 years of age or older
118. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study
119. Hypertension, cardiovascular disease, and age-related macular degeneration
120. The relation of cardiovascular disease and its risk factors to the 5-year incidence of age-related maculopathy: The Beaver Dam Eye Study
121. Sun exposure and age-related macular degeneration. An Australian case-control study
122. Dietary fat and fish intake and age-related maculopathy
123. Relationship of senile macular degeneration to ocular pigmentation
124. Decreasing stromal iris pigmentation as a risk factor for age-related macular degeneration
125. Iris color, skin sun sensitivity, and age-related maculopathy. The Blue Mountains Eye Study
126. The relationship of ocular factors to the incidence and progression of age-related maculopathy
127. Pigmentation of the eye and hair in relation to age-related macular degeneration. An epidemiological study of 1000 aged individuals
128. Age-related macular degeneration after extracapsular cataract extraction with intraocular lens implantation
129. Sunlight and age-related macular degeneration. The Beaver Dam Eye Study
130. Exposure to sunlight and other risk factors for age-related macular degeneration
131. Oxidative damage and age-related macular degeneration
132. The role of oxidative stress in the pathogenesis of age-related macular degeneration
133. Oxidative damage and protection of the RPE
134. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration
135. Antioxidant status and neovascular age-related macular degeneration
136. Are antioxidants or supplements protective for age-related macular degeneration?
137. Serum antioxidants and age-related macular degeneration in a population-based case-control study
138. Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study
139. Association of zinc and antioxidant nutrients with age-related maculopathy
140. Serum beta carotene, alpha tocopherol, and age-related maculopathy: The Blue Mountains Eye Study
141. Dietary antioxidants and age-related maculopathy: The Blue Mountains Eye Study
142. Age-related macular degeneration and antioxidant status in the POLA study
143. Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy
144. Moderate wine consumption is associated with decreased odds of developing age-related macular degeneration in NHANES-1
145. Alcohol use and age-related maculopathy in the Beaver Dam Eye Study
146. Alcohol intake and age-related maculopathy
147. A prospective study of alcohol consumption and the risk of age-related macular degeneration
148. Prospective study of alcohol consumption and the risk of age-related macular degeneration
149. Evolution of geographic atrophy of the retinal pigment epithelium
150. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture
151. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane
152. Aging human RPE: Morphometric analysis of macular, equatorial, and peripheral cells
153. The fate of the phagosome: Conversion to 'age pigment' and impact in human retinal pigment epithelium
154. Age-related changes in the ultrastructure of Bruch's membrane
155. Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration
156. Pathogenesis of drusen in the primate
157. Cellular mechanisms of resolution of drusen after laser coagulation. An experimental study
158. Senile macular degeneration: The involvement of immunocompetent cells
159. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging
160. Aging and Bruch's membrane
161. Age-related variation in the hydraulic conductivity of Bruch's membrane
162. Decreasing hydraulic conductivity of Bruch's membrane: Relevance to photoreceptor survival and lipofuscinoses
163. Hydrodynamics of ageing Bruch's membrane: Implications for macular disease
164. Localization of the site of major resistance to fluid transport in Bruch's membrane
165. Retinal pigment epithelial detachments in the elderly
166. The anterior lens capsule used as support material in RPE cell-transplantation
167. Propagation of fetal human RPE cells: Preservation of original culture morphology after serial passage
168. Bcl-2, Bax, and c-Fos expression correlates to RPE cell apoptosis induced by UV-light and daunorubicin
169. In vitro transplantation of fetal human retinal pigment epithelial cells onto human cadaver Bruch's membrane
170. Reattachment rate of human retinal pigment epithelium to layers of human Bruch's membrane
171. Fate of human retinal pigment epithelial cells seeded onto layers of human Bruch's membrane
172. Repopulation of different layers of host human Bruch's membrane by retinal pigment epithelial cell grafts
173. Transplanted and repopulated retinal pigment epithelial cells on damaged Bruch's membrane in rabbits
174. Lipofuscin accumulation in cultured retinal pigment epithelial cells causes enhanced sensitivity to blue light irradiation
175. Photodamage to human RPE cells by A2-E, a retinoid component of lipofuscin
176. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells
177. Lipofuscin and other lysosomal storage deposits in the retinal pigment epithelium
178. Age-related macular degeneration: Review of pathogenesis
179. Epithelium-capillary interactions in the eye: The retinal pigment epithelium and the choriocapillaris
180. RPE destruction causes choriocapillary atrophy
181. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy
182. The 220-kDa rim protein of retinal rod outer segments is a member of the ABC transporter superfamily
183. Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease
184. Photoreceptor 'retinoid pumps' in health and disease
185. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration
186. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice
187. Accumulation of cholesterol with age in human Bruch's membrane
188. Macrophages related to Bruch's membrane in age-related macular degeneration
189. Granulomatous reaction to Bruch's membrane in age-related macular degeneration
190. A potential role for immune complex pathogenesis in drusen formation
191. Biological implications of macrophage infiltration in human tumor angiogenesis
192. Current status of antiangiogenic factors
193. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1 alpha
194. Morphology of early choroidal neovascularisation in age-related macular degeneration: Correlation with activity
195. Human retinal pigment epithelial cell-induced apoptosis in activated T cells
196. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis
197. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization
198. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes
199. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation
200. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium
201. A novel mechanism for age-related macular degeneration: An equilibrium shift between the angiogenesis factors, VEGF and PEDF
202. Ocular blood flow velocity in age-related macular degeneration
203. Foveolar choroidal blood flow in age-related macular degeneration
204. Presumed macular choroidal watershed vascular filling, choroidal neovascularization, and systemic vascular disease in patients with age-related macular degeneration
205. A hemodynamic model of the pathogenesis of age-related macular degeneration
206. Increased scleral rigidity and age-related macular degeneration
207. Lutein and zeaxanthin in the eyes, serum and diet of human subjects
208. Macular pigment in donor eyes with and without AMD: A case-control study
209. A one year study of the macular pigment: The effect of 140 days of a lutein supplement
210. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration
211. Visual function and subjective quality of life compared in subjects with acquired macular disease
212. Six-year supplementation with alpha-tocopherol and beta-carotene and age-related maculopathy
213. Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract
214. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: Effects of base-line characteristics and study compliance
215. Antioxidant vitamin and mineral supplementation for preventing age-related macular degeneration
216. The Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
217. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
218. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial
219. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease
220. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study
221. The VECAT study: Methodology and statistical power for measurement of age-related macular features. Vitamin E, Cataract, and Age-related Maculopathy Study
222. Design of Physicians' Health Study II -a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials
223. Randomized trials of primary prevention of cardiovascular disease in women. An investigator's view
224. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods
225. Oral zinc in macular degeneration
226. Oral zinc and the second eye in age-related macular degeneration
227. Visaline in the treatment of age-related macular degeneration: A pilot study
228. Multicenter ophthalmic and nutritional age-related macular degeneration study -part 1: Design, subjects and procedures
229. Multicenter ophthalmic and nutritional age-related macular degeneration study -part 2: Antioxidant intervention and conclusions
230. Antioxidant vitamin and mineral supplements for age-related macular degeneration
231. The Age-Related Eye Disease Study (AREDS): Design implications AREDS report no. 1
232. Laser prophylaxis
233. Drusen in age-related macular degeneration: Pathogenesis, natural course, and laser photocoagulation-induced regression
234. Drusen and disciform macular detachment and degeneration
235. Photocoagulation of macular lesions
236. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications
237. Laser photocoagulation of soft drusen in early age-related maculopathy (ARM). The one-year results of a prospective, randomised trial
238. A pilot randomized controlled study on the effect of laser photocoagulation of confluent soft macular drusen
239. Laser-induced drusen reduction improves visual function at 1 year
240. The choroidal neovascularization prevention trial (CNVPT): 4-Year results
241. Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: Two-year results of a randomized pilot study
242. Therapeutic benefits of diode laser grid photocoagulation in prophylactic treatment of age-related macular degeneration (AMD). Long term (4-5 years) results of a randomized pilot study
243. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial
244. Results of the age-related macular degeneration and thalidomide study (AMDATS)
245. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate
246. Exudative macular degeneration and intravitreal triamcinolone: 18 Month follow up
247. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration
248. The safety of single intravitreal injection of triamcinolone among patients with age-related macular degeneration. One year results of a randomised clinical trial: IVTAS
249. The efficacy of a single intravitreal injection of triamcinolone for neovascular age-related macular degeneration. One year results of a randomised clinical trial: IVTAS
250. Sub-Tenon's retrobulbar anecortave acetate with and without Visudyne™ photodynamic therapy (PDT) in patients with subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD)
251. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity
252. Sub-Tenon's retrobulbar anecortave acetate with and without Visudyne PDT in patients with subfoveal age-related macular degeneration (AMD) - A review of the emerging clinical safety profile of this new experimental treatment
253. Anti-VEGF Therapy in patients with exudative age-related macular degeneration
254. Safety of rhuFab V2, an anti-VEGF antibody fragment, as a single intravitreal injection in subjects with neovascular age-related macular degeneration
255. Safety evaluation of differing schedules of intravitreal administration of rhuFab VEGF in cynomolgus monkeys for two months
256. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor
257. A light microscopic and autoradiographic study of non-irradiated and irradiated ocular wounds
258. Treatment of age-related subfoveal neovascular membranes by teletherapy: A pilot study
259. Radiation therapy
260. Radiotherapy for age-related macular degeneration: Preliminary results of a potentially new treatment
261. Radiation therapy for subfoveal choroidal neovascular membranes in age-related macular degeneration. A pilot study
262. Radiation therapy for age-related subfoveal choroidal neovascular membranes. A pilot study
263. Treatment of age-related subfoveal neovascular membranes by teletherapy: Results of a non-randomized study
264. Teletherapy for subfoveal choroidal neovascularisation of age-related macular degeneration: Results of follow up in a non-randomised study
265. External radiotherapy in macular degeneration: Technique and preliminary subjective response
266. External beam radiation therapy for choroidal neovascularization
267. External beam radiotherapy (20 Gy, 2 Gy fractions) fails to control the growth of choroidal neovascularization in age-related macular degeneration: A review of 111 cases
268. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study)
269. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: Radiation versus observation
270. Randomized trial of radiation for age-related macular degeneration
271. Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularization
272. Treatment of macular degeneration with proton beams
273. Phase I/II study of proton beam irradiation for the treatment of subfoveal choroidal neovascularization in age-related macular degeneration: Treatment techniques and preliminary results
274. Proton beam irradiation of subfoveal choroidal neovascularisation in age-related macular degeneration
275. Radiation-associated choroidal neovasculopathy
276. Comparison of krypton and argon laser photocoagulation. Results of stimulated clinical treatment of primate retina
277. Clinicopathologic studies of treated choroidal neovascular membranes. A review and report of two cases
278. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration
279. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial
280. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials
281. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration
282. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity
283. Evaluation of argon green vs krypton red laser for photocoagulation of subfoveal choroidal neovascularization in the macular photocoagulation study
284. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials
285. Choroidal neovascularization. Treatment guidelines for age-related macular degeneration based upon results from the macular photocoagulation study
286. Detecting recurrent choroidal neovascularization. Comparison of clinical examination with and without fluorescein angiography
287. Growth features of choroidal neovascular membranes in age-related macular degeneration
288. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial
289. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial
290. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial
291. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes. Submacular surgery trials pilot study report number 1(2)
292. Macular scatter ('grid') laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration. Results of a randomized pilot trial
293. Controlled trial of laser photocoagulation of pigment epithelial detachments in the elderly: 4 Year review
294. Indocyanine green-guided laser photocoagulation of focal spots at the edge of plaques of choroidal neovascularization
295. A pilot study of indocyanine green videoangiography-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration
296. Indocyanine green angiography. Can it help preserve the vision of our patients?
297. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration
298. Transpupillary thermotherapy for age-related macular degeneration: Long-pulse photocoagulation, apoptosis, and heat shock proteins
299. Photodynamic therapy for choroidal neovascularization and age-related macular degeneration
300. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization
301. Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative
302. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys
303. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin
304. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment
305. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey
306. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a phase 1 and 2 study
307. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-Year results of a randomized clinical trial -VIP report no. 1
308. Rationale for and design of the Visudyne in Early Retreatment (VER) Trial
309. Update in retina: Photodynamic therapy for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration
310. Incidence of predominantly classic choroidal neovascular membranes (CNV) in exudative age related macular degeneration (AMD): Percentage of new patients eligible for photodynamic therapy with verteporfin
311. Photodynamic therapy with tin ethyl etiopurpurin (SnET2) of subfoveal choroidal neovascularization (CNV) in age-related maculopathy: Study design and baseline characteristics
312. Preliminary results from a phase II dose-response study of photodynamic therapy with motexafin lutetium(Lu-Tex™) to treat subfoveal CNV
313. Lutetium texaphyrin (Lu-Tex): A potential new agent for ocular fundus angiography and photodynamic therapy
314. Photodynamic angiography: A new technique utilizing lutex
315. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: II Quality of life outcomes. Submacular surgery trials pilot study report number 2
316. Submacular surgery
317. Surgical removal of subfoveal choroidal neovascularization in age-related macular degeneration
318. Surgical extraction of subfoveal choroidal new vessels and submacular haemorrhage in age-related macular degeneration: Results of a prospective study
319. Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration
320. Decreased choriocapillaris perfusion following surgical excision of choroidal neovascular membranes in age-related macular degeneration
321. Pigment epithelium defects after submacular surgery for choroidal neovascularization: First results
322. Clinicopathologic studies of an eye after submacular membranectomy for choroidal neovascularization
323. Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-beta 2, and gas tamponade
324. Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD
325. Transplantation of RPE in age-related macular degeneration: Observations in disciform lesions and dry RPE atrophy
326. Iris pigment epithelial cell translocation in exudative age-related macular degeneration. A pilot study in patients
327. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration
328. Factors prognostic of visual outcome in patients with subretinal hemorrhage
329. Fibrin directs early retinal damage after experimental subretinal hemorrhage
330. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator
331. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas
332. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement
333. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits
334. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes
335. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration?
336. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration
337. Macular translocation for surgical management of subfoveal choroidal neovascularizations in patients with AMD: First results
338. Translocation of the retina for management of subfoveal choroidal neovascularization II: A preliminary report in humans
339. Complications associated with limited macular translocation
340. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration
341. Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: A prospective study
342. Macular translocation
343. Transpupillary thermotherapy in choroidal melanomas
344. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration
345. A randomized, placebo-controlled clinical trial of high dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss